Yorvipath denied for failing step therapy by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applied Step Therapy to Yorvipath — and How to Challenge It

Step-therapy ("fail-first") denials for Yorvipath (palopegteriparatide) require patients to try and document failure of one or more conventional treatments before Humana will approve the requested drug. For hypoparathyroidism managed with Yorvipath, this most often means demonstrating that conventional calcium and active vitamin D supplementation was tried and found inadequate for this patient. These denials are strongly appellable when the prior-treatment history is well-documented — because for many patients seeking Yorvipath, that prior-treatment failure is precisely why the prescriber requested it.

## Why This Is Appealable

Step-therapy appeals succeed when the appeal demonstrates two things: first, that the required prior steps were genuinely taken (with dates and outcomes), and second, that the step-therapy requirement — as applied — either conflicts with the FDA-approved labeling or imposes a clinical burden that is not supported by the endocrinology guideline standard of care. Relevant professional guideline organizations address the clinical contexts in which hormone-replacement therapy is appropriate for this population; your prescriber can reference those organizations' positions. Additionally, many states have enacted step-therapy override laws that provide additional protection, particularly where step therapy conflicts with FDA labeling or established guidelines.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal with full clinical documentation of prior-treatment history. Submit within the deadline on the denial letter.
• Step-therapy override statutes: If the plan is subject to state insurance law (not solely ERISA), check whether your state's step-therapy override law applies. These laws often require the insurer to waive the step-therapy requirement when guideline-recommended prior steps have failed.
• External review (ACA §2719): After internal denial, escalate to an IRO. The IRO evaluates whether the step-therapy requirement is clinically appropriate given the patient's documented history and the FDA label. Standard window is up to four months; expedited option available.

## Documentation to Gather

1. Complete prior-treatment history — this is the most important document. List every conventional therapy attempted before Yorvipath was requested: specific agents, start dates, end dates, clinical response (laboratory and symptomatic), and documented reason for discontinuation or inadequacy. Include all relevant chart notes, lab results, and pharmacy records. 2. Diagnosis confirmation — laboratory and clinical records confirming the hypoparathyroidism diagnosis, etiology, and duration. 3. Symptom burden documentation — records of inadequate disease control on conventional therapy: symptomatic episodes, laboratory instability, or end-organ complications documented with dates. 4. Prescriber letter — the endocrinologist should address each step-therapy requirement by name, confirm which steps have been completed and with what outcome, and explain why Yorvipath is the appropriate next step per the applicable guideline organization's recommendations. 5. FDA-approved label — review the label's clinical context; if it references prior-treatment inadequacy as part of the indication, cite that language directly.

## Criteria-Mapping Strategy

Obtain Humana's step-therapy criteria for Yorvipath from the denial letter or Humana's published policy. Create a table with each required step in the left column and the specific chart documentation of completion (or clinical bypass reason) in the right column. Submit this table with the prescriber letter as the opening pages of the appeal. A clear, criterion-by-criterion demonstration that the required steps are already complete — or clinically inappropriate — is the most efficient path to overturn.